Pertuzumab (re-assessment: early breast cancer, high risk of recurrence, adjuvant therapy, in combination with trastuzumab and chemotherapy)



  • Active Substance: Pertuzumab
  • Name: Perjeta®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: Roche Pharma AG


Time table:

  • Start: 01.10.2022
  • Publication of assessment: 02.01.2023
  • End of public hearing: 23.01.2023
  • Final decision by G-BA: middle of March 2023


Comparative therapy:

  • A therapy scheme including trastuzumab, a taxane (paclitaxel or docetaxel) and, if necessary, an anthracycline (doxorubicine or epirubicin)